Neurosurgical approach

Cancer Journal

Volumn 18, Issue 1, 2012, Pages 20-25

  Moliterno, Jennifer A ^a   Patel, Toral R ^a   Piepmeier, Joseph M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glioblastoma; surgical treatment

Indexed keywords

AMINOLEVULINIC ACID; CAMPTOTHECIN; CINTREDEKIN BESUDOTOX; DENDRIMER; LIPID; LIPOSOME; NANOPARTICLE; TEMOZOLOMIDE;

BRAIN BLOOD VOLUME; BRAIN CORTEX; BRAIN ISCHEMIA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIFFUSION TENSOR IMAGING; DRUG IMPLANT; ELECTROSTIMULATION; FRACTIONAL ANISOTROPY; GLIOBLASTOMA; HUMAN; IMAGE QUALITY; MICELLE; MONITORING; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; NEUROLOGIC DISEASE; NEURORADIOLOGY; NEUROSURGEON; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; STEREOTACTIC RADIOSURGERY; SURGICAL APPROACH; SURGICAL TECHNIQUE; TRACTOGRAPHY; TUMOR BIOPSY; TUMOR LOCALIZATION; TUMOR NECROSIS; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; GLIOBLASTOMA; HUMANS; MIDDLE AGED;

EID: 84856699237     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3183243f6e3     Document Type: Review

References (52)

1. Laws ER, Parney IF, Huang W, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg. 2003;99:467-473. (Pubitemid 37040405)
2. Stummer W, van den Bent MJ, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochir (Wien). 2011;153:1211-1218.
3. Hess KR. Extent of resection as a prognostic variable in the treatment ofgliomas. JNeurooncol. 1999;42:227-231. (Pubitemid 29322199)
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus con-comitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
5. Mc Girt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg. 2009;110:156-162.
6. Sanai N, Polley MY, Mc Dermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011; 115:3-8.
7. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study ofclinical parameters, therapy, andoutcome. JNeurosurg. 1993;78:767-775.
8. Sawaya R. Extent of resection in malignant gliomas: a critical summary. J Neurooncol. 1999;42:303-305. (Pubitemid 29322205)
9. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent ofresec-tion, and survival. JNeurosurg. 2001;95:190-198. (Pubitemid 32799739)
10. Simpson JR, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival ofpatients with glioblastoma multiforme: results ofthree consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys. 1993;26:239-244. (Pubitemid 23156970)
11. Kowalczuk A, Macdonald RL, Amidei C, et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astro-cytomas. Neurosurgery. 1997;41:1028-1036; discussion 1036-1038.
12. Quigley MR, Maroon JC. The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 1991;29:385-388; discussion 388-389.
13. Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy ofmalig-nant glioma in elderly people-a randomised study. Acta Neurochir (Wien). 2003;145:5-10. (Pubitemid 36174074)
14. Curran WJ Jr, Scott CB, Horton J, et al. Does extent ofsurgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol. 1992;12:219-227.
15. Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival. J Neurooncol. 2011;103:611-618.
16. Kelly PJ, Hunt C. The limited value ofcytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery. 1994;34:62-66; discus-sion 66-67.
17. van den Bent MJ, Stupp R, Mason W, et al. Impact ofextent ofresec-tion on overall survival in newly-diagnosed glioblastoma after chemo-irradiation with temozolomide: further analysis of EORTC study 26981 [abstract]. Eur J Cancer. 2005;[suppl 2]:134.
18. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided sur-gery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006; 7:392-401.
19. Nelson SJ, Cha S. Imaging glioblastoma multiforme. Cancer J. 2003; 9:134-145.
20. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology. 1994;191:41-51.
21. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology. 1999;211:791-798. (Pubitemid 29249482)
22. Cha S, Knopp EA, Johnson G, et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with tha-lidomide and carboplatin. AJNRAm J Neuroradiol. 2000;21:881-890. (Pubitemid 30262835)
23. Nelson SJ. Analysis of volume MRI and MR spectroscopic imaging data for the evaluation ofpatients with brain tumors. Magn Reson Med. 2001;46:228-239. (Pubitemid 32703267)
24. Pirzkall A, Mc Knight TR, Graves EE, et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys. 2001;50:915-928. (Pubitemid 32594834)
25. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity and predictive values of perfusion MR imaging and proton MR spectro-scopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24:1989-1998. (Pubitemid 37444849)
26. Moller-Hartmann W, Herminghaus S, Krings T, et al. Clinical applica-tion of proton magnetic resonance spectroscopy in the diagnosis of in-tracranial mass lesions. Neuroradiology. 2002;44:371-381. (Pubitemid 36097186)
27. Dean BL, Drayer BP, Bird CR, et al. Gliomas: classification with MR imaging. Radiology. 1990;174:411-415. (Pubitemid 20038599)
28. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and his-topathology ofcerebral gliomas. Neuroradiology. 1992;34:463-469.
29. Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contem-porary neurodiagnostic imaging in evaluating suspected adult supraten-torial (low-grade) astrocytoma. J Neurosurg. 1993;79:533-536. (Pubitemid 23289810)
30. Hammoud MA, Sawaya R, Shi W, et al. Prognostic significance ofpre-operative MRI scans in glioblastoma multiforme. J Neurooncol. 1996; 27:65-73. (Pubitemid 26052641)
31. Brunberg JA, Chenevert TL, Mc Keever PE, et al. In vivo MR determi-nation ofwater diffusion coefficients and diffusion anisotropy: correla-tion with structural alteration in gliomas of the cerebral hemispheres. AJNRAm J Neuroradiol. 1995;16:361-371.
32. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation ofcellularity in glio-mas. JMagn Reson Imaging. 1999;9:53-60. (Pubitemid 29068231)
33. Baehring JM, Bi WL, Bannykh S, et al. Diffusion MRI in the early diagnosis ofmalignant glioma. J Neurooncol. 2007;82:221-225. (Pubitemid 46431869)
34. Awasthi R, Verma SK, Haris M, et al. Comparative evaluation of dynamic contrast-enhanced perfusion with diffusion tensor imaging metrics in assessment of corticospinal tract infiltration in malignant glioma. JComput Assist Tomogr. 2010;34:82-88.
35. Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol. 2011;12:997-1003.
36. Sherman JH, Hoes K, Marcus J, et al. Neurosurgery for brain tumors: update on recent technical advances. Curr Neurol Neurosci Rep. 2011; 11:313-319.
37. Leclercq D, Duffau H, Delmaire C, et al. Comparison of diffusion tensor imaging tractography of language tracts and intraoperative subcortical stimulations. JNeurosurg. 2010;112:503-511.
38. Leclercq D, Delmaire C, de Champfleur NM, et al. Diffusion tracto-graphy: methods, validation and applications in patients with neurosur-gical lesions. Neurosurg Clin NAm. 2011;22:253-268, ix.
39. Allard E, Passirani C, Benoit JP. Convection-enhanced delivery ofnano-carriers for the treatment of brain tumors. Biomaterials. 2009;30: 2302-2318.
40. Attenello FJ, Mukherjee D, Datoo G, et al. Use of Gliadel (BCNU) wafer in the surgical treatment ofmalignant glioma: a 10-year institu-tional experience. Ann Surg Oncol. 2008;15:2887-2893.
41. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local che-motherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5:79-88. (Pubitemid 36422560)
42. Brem H, Mahaley MS Jr, Vick NA, et al. Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg. 1991;74:441-446.
43. Fung LK, Shin M, Tyler B, et al. Chemotherapeutic drugs released from polymers: distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea in the rat brain.Pharm Res. 1996;13:671-682. (Pubitemid 26156217)
44. Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med. 2006;79:141-152.
45. Bobo RH, Laske DW, Akbasak A, et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994;91: 2076-2080. (Pubitemid 24092045)
46. Jacobs A, Voges J, Reszka R, et al. Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas. Lancet. 2001;358:727-729. (Pubitemid 32823405)
47. Sampson JH, Akabani G, Archer GE, et al. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol. 2008;10:320-329.
48. Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 2010;12:871-881.
49. Sawyer AJ, Saucier-Sawyer JK, Booth CJ, et al. Convection-enhanced delivery ofcamptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv Transl Res. 2011;1:34-42.
50. Noble CO, Krauze MT, Drummond DC, et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res. 2006;66:2801-2806.
51. Saito R, Krauze MT, Noble CO, et al. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model. Neuro Oncol. 2006;8:205-214. (Pubitemid 46542645)
52. Mamot C, Nguyen JB, Pourdehnad M, et al. Extensive distribution of liposomes in rodent brains and brain tumors following convection-enhanced delivery. J Neurooncol. 2004;68:1-9. (Pubitemid 39137344)